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The cytokine-inducible SH2-containing protein (CIS, 
encoded by Cish) is a member of the suppressors of cytokine 
signaling (SOCS), a family of intracellular proteins that 
have been show to regulate the activity of a variety of 
cytokine and growth factor receptors (1). Similar to the 
other members, CIS presents a central SH2-domain able 
to interact with phosphotyrosine residues and a SOX box 
motif that recruits the ubiquitin-transferase system (u-ts) 
and directs targeted proteins to proteasomal degradation. 
CIS has also been shown to interact with the cytoplasmic 
domains and suppress the signals of different receptors 
including the IL-2R (2). In the study recently published 
in nature immunology (3), Delconte and colleagues 
analyze the role of CIS in regulating the IL-15 signaling 
pathway in NK cells. This pathway includes signals that 
are transmitted through the IL-2Rβ (CD122) and γc 
(CD132) subunits that, upon engagement, associate and 
activate JAK1 and JAK3 (Figure 1). It follows STAT5 
activation that induces the transcription of genes involved 
in the survival, proliferation and function of NK cells (4). 
The authors deepened the regulatory role of CIS in 
mouse NK cells using a Cish-deleted model (Cish−/−). 
They show that CIS is expressed early during NK cells 
differentiation and that saturating high concentrations of 
IL-15 increased its expression at both mRNA and protein 
level. Cish−/− NK cells showed upregulation of IL-2Rβ 
expression and hyper-responsiveness to IL-15, which 
resulted in increased survival, proliferation, cytotoxicity 
and IFN-γ  production as compared to Cish +/+ NK 
cells (Figure 1). Moreover, in Cish−/− NK cells cytokine 
stimulation modulated more than 1,000 genes, including 
those coding for granzymes, and increased phosphorylation 
of 69 kinases including JAK-1, JAK-3, STAT5 and kinases 
mainly involved in regulating cellular proliferation such as 
CDK1/2, Prkr and Aurora kinases. By using a recombinant 
trimeric complex formed by a human CIS-SH2 construct 
coupled to elongins B and C, the authors show that CIS, 
similar to SOCS-1 and SOCS-3, binds to JAK-1 and 
JAK3. CIS, which lacks the kinase inhibitor region (KIR), 
interact with JAK1 via the SH2 domain, targets JAK1 to 
proteosomal degradation and inhibits its enzymatic activity 
(Figure 1), although with an efficacy 100 fold lower than 
SOCS1. It has been previously published that exposure of 
mouse NK cells to high concentrations of IL-15 results 
in the activation of the evolutionarily conserved serine-
threonine kinase mTOR (mammalian target of rapamycin 
complex) a crucial metabolic checkpoint regulating 
translation and glycolytic pathway in both homeostatic and 
pro-inflammatory conditions (5). Although CIS and mTOR 
share analogy in the mechanisms of induction, the two 
pathways appear to be disconnected. Indeed, in Cish−/− NK 
cells IL-15 does not increase the phosphorylation of AKT, 
that represents a crucial event during mTOR activation (6). 
In line with this observation, Cish−/− NK cells show normal 
mitochondrial respiration and glycolysis, functions that are 
regulated by the AKT activity. 
Cish−/− mice apparently are healthy and display normal 
NK and T lymphocytes frequency and phenotype (3). 
According to an increased activity of CIS-deficient immune 
cells, Cish−/− mice show fewer lung metastases than Cish+/+ 
when intravenous injected with melanoma, prostate or 
breast cancer tumor cell lines, a protective effect that is 
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Figure 1 Regulatory role of CIS in IL-15 stimulated NK cells. 
The IL-15 binding to the receptor activates JAK1 (JAK3) 
and STAT5 leading to the transcription of genes regulating 
survival, proliferation and effector functions of NK cells. A high 
IL-15 concentration leads to the transcription of Cish whose 
product binds IL-2Rβ and JAKs. CIS inhibits JAK1 tyrosine 
phosphorylation and drives JAK1 to proteasomal degradation 
thanks to the recruitment of the ubiquitin-transferase system (u-ts). 
In Cish−/− mice NK cells show increased responsiveness to IL-15. 
CIS, cytokine-inducible SH2-containing protein.
mainly dependent on the effector function of NK cells. 
Finally, even fewer metastases were detected in Cish−/− 
mice treated with a combination of anti-PD-1 and anti-
CTLA-4 mAbs (7-9). Since CIS is induced by high 
concentrations of IL-15, the authors suggest that, in the 
mouse model used, NK cells might receive such intense 
stimulus from the inflammatory tumor microenvironment. 
In particular, immune cells colonizing tumor tissues, such as 
dendritic cells or macrophages, might “trans-present” high 
concentrations of IL-15 to NK cells. 
Overall, the study demonstrates that CIS represents a 
negative feedback mechanism activated not only by IL-2 (2) 
but also by IL-15 switching off NK cells effector functions 
including cytotoxicity against tumor cells (4,10,11). In 
this context, a recent paper showed that in CD8+ T cells 
CIS inhibits the TCR signaling by physically interacting 
with the TCR intermediate PLC-γ1 and targeting it for 
proteasomal degradation (12). The Authors also propose 
CIS as a novel immune checkpoint and highlight the 
potential benefit of therapies combining CIS inhibition and 
low doses of IL-15 to improve anti-tumor NK cell function 
in patients.
Importantly however, the information on CIS is still 
scarce and we cannot underestimate the possible side 
effects of unleashing the function of lymphocytes with 
high cytolytic and proliferative capacity. Moreover, a 
conditio sine qua non will be to inactivate CIS in selected 
and specific target cells. It can’t be disregarded previous 
observations showing that CIS expression is not restricted to 
lymphocytes but is present in other normal tissues including 
kidney, lung, liver, stomach and heart thus suggesting that 
it may represent a wide type of regulatory molecule (1,13). 
Moreover, CIS was shown to interact and regulate highly 
pleiotropic receptors including the growth hormone (1). 
Although Cish−/− mice were healthy, fertile and with no 
evidence of phenotypic or immunological abnormalities, 
further studies are needed to exclude that CIS targeting 
might result in dangerous dysregulation or breaking of 
crucial feedback mechanisms that tune important cellular 
functions in both hematopoietic and non-hematopoietic 
tissues. At this regard, a recent study shows that aged Cish−/− 
mice develop an inflammatory lung condition associated 
with altered IL-4-STAT6 and IL-2-STAT5 signaling in 
CD4+ T cells (14). Moreover CIS and SOCS1–7 would 
play a key role in regulation of cellular homeostasis and 
inflammation and are now regarded as tumor suppressors 
both in hematological and solid malignances (1). Indeed, 
a link has been demonstrated between reduced levels/
function of SOCS proteins (due to gene mutation/deletion 
or epigenetic mechanisms) and cancer development and 
progression (1). The role of some proteins belonging to 
this family could be even more complex. Indeed, SOCS-2, 
which is closely related to CIS (1), appears to play a dual 
opposite role, being able to control both growth factor 
receptors and other SOCS proteins depending on its 
concentration and cellular context. Last but not least, it is 
important to note that an untargeted CIS neutralization 
might strength not only the immune-stimulatory effects of 
IL-15 but also its pro-angiogenic property (15-17). 
In conclusion, the results by Delconte (and other 
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properties. However, data must be validated in the human 
system and further studies are required to demonstrate 
the absence of long-term systemic side effects of CIS 
inactivation and to translate the results into the clinical 
practice.
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